Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Li, Zhenxian;Zhu, Haimei;Liu, Hao;Liu, Dayue;Liu, Jianhe;...

通讯作者：

Long, Y;Liu, B

作者机构：

[Qin, Zhang; Zhang, Yi; Li, Zhenxian; Peng, Yuan; Xu, Yijia; Long, Yun; Liu, Jianhe; Jiang, Jiazheng] Hunan Univ Chinese Med, Hosp 1, Branch Natl Clin Res Ctr Chinese Med Cardiol, Dept Cardiol, Changsha 410007, Peoples R China.

[Liu, B; Liu, Bin] Hunan Univ, Coll Biol, Changsha 410082, Peoples R China.

[Liu, Hao] Cent South Univ, Xiangya Hosp 2, Dept Rehabil, Changsha 410011, Peoples R China.

[Liu, B; Liu, Dayue; Liu, Bin] Ningxia Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, NHC Key Lab Metab Cardiovasc Dis Res, Yinchuan 750004, Peoples R China.

[Zhu, Haimei] Hunan Univ Chinese Med, Hosp 1, Dept Pain, Changsha 410007, Peoples R China.

通讯机构：

[Liu, B ; Long, Y ] H

Hunan Univ Chinese Med, Hosp 1, Branch Natl Clin Res Ctr Chinese Med Cardiol, Dept Cardiol, Changsha 410007, Peoples R China.

Hunan Univ, Coll Biol, Changsha 410082, Peoples R China.

Ningxia Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, NHC Key Lab Metab Cardiovasc Dis Res, Yinchuan 750004, Peoples R China.

语种：

英文

关键词：

Atherosclerosis;Evolocumab;Proprotein convertase subtilisin/Kexin type 9;Liposome;Phenotypic transition

期刊：

Journal of Nanobiotechnology

ISSN：

1477-3155

年：

2023

卷：

期：

页码：

1-21

DOI：

10.1186/s12951-023-01904-4

基金类别：

This work was supported by the Research Project of Science and Technology Planning Project of Changsha (kq2202459), Key R&D Projects in Ningxia Hui Autonomous Region (2022BFH02013), Chinese medicine research Project of Hunan Province (A2023051), and the Natural Science Foundation of Hunan Province (2022JJ40698).

机构署名：

本校为第一且通讯机构

院系归属：

第一中医临床学院

摘要：

PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration of VSMCs play key roles in accelerating atherosclerosis. In this study, by utilizing the significant advantages of nano-materials, a biomimetic nanoliposome loading with Evolocumab (Evol), a PCSK9 inhibitor, was designed to alleviate atherosclerosis. In vitro results showed that (Lipo + M)...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问